ANDA 203167, held by Xgen Pharms. Clonidine Hydrochloride.
As of Nov 16, 2026, ANDA 203167 (Clonidine Hydrochloride), held by Xgen Pharms, was first approved by FDA on Oct 29, 2013, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Clonidine hydrochloride injection is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see Clinical Trials ). The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see WARNINGS ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 29, 2013 | Original application | Approved | None posted |
| Clonidine Hydrochloride1MG/10ML (0.1MG/ML) · injectable;injection | Clonidine Hydrochloride | Rx |
| Clonidine Hydrochloride5MG/10ML (0.5MG/ML) · injectable;injection | Clonidine Hydrochloride | Rx |
| Nov 3, 2026 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 29, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters